Publication
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Authors not recorded
Cancer Discov2016PMID 26739882stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Neoplasmcivic_curation1.00
- drugARS-853civic_curation1.00
- drugEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitorcivic_curation1.00
- geneKRAScivic_curation1.00
- variantKRAS G12Ccivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26739882
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS G12C1 | ||||||||
| ARS-853 + Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorCombination | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1173Preclinical study to investigate mechanisms of KRAS G12C activity and inhibition with ARS-853, a covalent (irreversible) inhibitor which binds KRAS G12C in the GDP-bound state to prevent activation. R… (full text at CIViC) PMID 26739882 · Patricelli et al., 2016 · Open in CIViC | civic |